These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 16691078)
1. Unexpected improvement of sexual dysfunction during atazanavir therapy. Colebunders R; Moerman F; Nöestlinger C AIDS; 2006 May; 20(8):1209-10. PubMed ID: 16691078 [No Abstract] [Full Text] [Related]
2. Unexpected improvement of sexual dysfunction during atazanavir therapy. Bernal E; Masiá M; Padilla S; Gutiérrez F AIDS; 2005 Sep; 19(13):1440-1. PubMed ID: 16103782 [No Abstract] [Full Text] [Related]
3. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112 [TBL] [Abstract][Full Text] [Related]
4. Does atazanavir cause lipodystrophy? Gazzard BG; Moyle G J HIV Ther; 2004 May; 9(2):41-4. PubMed ID: 15238875 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E; Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947 [TBL] [Abstract][Full Text] [Related]
7. [Metabolic changes in PI-based HAART. Change to atazanavir: continued effectiveness with improved lipid profile]. MMW Fortschr Med; 2008 Apr; 150 Spec No 1():42-3. PubMed ID: 19024917 [No Abstract] [Full Text] [Related]
8. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. Gianotti N; Guffanti M; Galli L; Margonato A; Chiaravalli G; Bigoloni A; Lazzarin A; Castagna A AIDS; 2007 Jul; 21(12):1648-51. PubMed ID: 17630564 [TBL] [Abstract][Full Text] [Related]
9. Anti-HIV agents. Atazanavir as a booster for protease inhibitors. TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850 [No Abstract] [Full Text] [Related]
10. Sexual dysfunction in the highly active antiretroviral therapy era. Collazos J AIDS Rev; 2007; 9(4):237-45. PubMed ID: 18219367 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977 [TBL] [Abstract][Full Text] [Related]
16. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes. Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415 [TBL] [Abstract][Full Text] [Related]